AHA Statement on FY 2021 Final IPPS Rule

AHA Statement on FY 2021 Final IPPS Rule

Ashley Thompson
Senior Vice President, Public Policy Analysis and Development
American Hospital Association

 

September 2, 2020


The AHA remains deeply disappointed that CMS continues to require hospitals and health systems to disclose privately negotiated contract terms with payers. By continuing to focus on negotiated rates rather than expanding access to a patient’s out-of-pocket costs, the Administration fails to meet the goal it set for itself - assisting consumers in becoming more prudent purchasers of health care. We once again urge the agency to focus on what is really important to patients - ready access to their out-of-pocket costs.

Additionally, this policy will require hospitals to divert critically needed resources during this historic pandemic to administrative tasks that will not benefit patients. We do not believe CMS has the authority to compel the disclosure of these terms and our legal challenge remains ongoing.


While we appreciate the agency’s focus in addressing cost issues for life-saving CAR T therapy, we remain concerned that the policy the agency has put forth in this final rule is not adequate to address the extraordinary level of resources necessary to provide CAR T therapy to patients. We continue to urge CMS to consider an alternative method of determining the cost of CAR T therapy, as well as to consider carving out these very costly new technologies from the MS-DRG and paying for them on a pass-through basis.

###

Contact:        Colin Milligan, (202) 638-5491, cmilligan@aha.org
                      Marie Johnson, (202) 626-2351, mjohnson@aha.org
 

 

Related Resources

Webinar Recordings
Member
Your browser does not support the video tag.
Guides/Reports
Public
In 2017 alone, 340B Tax-exempt Hospitals Provided More Than $64 Billion in Total Benefits to Their Communities   Improving the health of their…
Action Alert
Member
In response to recent actions taken by a number of drug companies to limit the distribution of certain 340B drugs to hospitals and health systems, Reps. Diana…
Letter/Comment
Public
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our…
Letter/Comment
Public
On behalf of the nation’s 340B hospitals, AHA, others urge the Department of Health and Human Services (HHS) to protect vulnerable communities from actions…
Letter/Comment
Public
AHA expresses profound concern about actions Eli Lilly and Company is taking to collect data intended to limit the distribution of certain 340B drugs to…